Clinical Trial Update: A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating RG2417 for Bipolar I Depression has completed, assessing safety, tolerability and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Depression

Drugs mentioned

• RG2417

Snippet

Sponsor: Repligen Corporation | Conditions: Bipolar I Depression | Phase 2 | Status: COMPLETED